{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:19Z","timestamp":1792784599683,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Arthritis, Musculoskeletal and Skin Diseases","award":["AR 65932"],"award-info":[{"award-number":["AR 65932"]}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire, Protalix Biotherapeutics and Amicus Therapeutics"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ymgme.2016.11.006","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T15:31:51Z","timestamp":1479396711000},"page":"8-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Gaucher disease: Progress and ongoing challenges"],"prefix":"10.1016","volume":"120","author":[{"given":"Pramod K.","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grisel","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman W.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.11.006_bb0005","series-title":"De L'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie","author":"Gaucher","year":"1882"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00000441-190104000-00001","article-title":"Primary splenomegaly with a report of three cases occuring in one family","volume":"121","author":"Brill","year":"1901","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0015","series-title":"Rev Franc de Ped III","first-page":"475","author":"Oberling C","year":"1927"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0020","series-title":"La maladie de Gaucher dans l'enfance, Facult\u00e9 de M\u00e9dicine, Paris","author":"E.","year":"1934"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0025","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1172\/JCI104175","article-title":"Cerebroside synthesis in Gaucher's disease","volume":"39","author":"Trams","year":"1960","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0021-9258(18)97611-8","article-title":"The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue","volume":"240","author":"Brady","year":"1965","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0040","doi-asserted-by":"crossref","first-page":"17C","DOI":"10.1042\/bj0970017C","article-title":"A deficiency of glucocerebrosidase in Gaucher disease","volume":"97","author":"Patrick","year":"1965","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM196608112750606","article-title":"The sphingolipidoses","volume":"275","author":"Brady","year":"1966","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0050","series-title":"Pharmaceutical Enzymes","first-page":"261","article-title":"Macrophage-targeted glucocerebrosidase: a therapeutically effective enzyme replacement product for Gaucher disease","year":"1997"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0055","first-page":"186","article-title":"Zur Kenntnis der Splenomegalie Gaucher, insbesondere der Histogenese der Grobzellen Wucherung Z","volume":"7","author":"Kraus","year":"1920","journal-title":"Angew. Anat."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0060","first-page":"303","article-title":"Gaucher's disease in Norrbotten","volume":"61","author":"Hillborg","year":"1959","journal-title":"Nordisk Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.155.3758.86","article-title":"Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood","volume":"155","author":"Kampine","year":"1967","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0070","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0022-3476(72)80245-2","article-title":"Infantile (type II) Gaucher's disease: in utero diagnosis and fetal pathology","volume":"81","author":"Schneider","year":"1972","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0005-2744(68)90251-9","article-title":"The lysosomal localization of sphingolipid hydrolases","volume":"159","author":"Weinreb","year":"1968","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0080","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/S0021-9258(19)43595-3","article-title":"Isolation and characterization of glucocerebrosidase from human placental tissue","volume":"248","author":"Pentchev","year":"1973","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0085","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1073\/pnas.74.8.3560","article-title":"Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration","volume":"74","author":"Furbish","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-291X(80)91489-8","article-title":"A new group of glucocerebrosidase isozymes found in human white blood cells","volume":"97","author":"Ginns","year":"1980","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0095","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1073\/pnas.79.18.5607","article-title":"Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease","volume":"79","author":"Ginns","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM198407123110203","article-title":"Bone-marrow transplantation in severe Gaucher's disease","volume":"311","author":"Rappeport","year":"1984","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0105","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1016\/S0021-9258(18)90936-1","article-title":"Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase","volume":"259","author":"Takasaki","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-3101(24)00142-7","article-title":"Gaucher's disease: advances and challenges","volume":"36","author":"Martin","year":"1989","journal-title":"Adv. Pediatr."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0115","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1016\/S0021-9258(19)78077-6","article-title":"Identification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry","volume":"269","author":"Miao","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0120","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.82.20.7101","article-title":"Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease","volume":"82","author":"Ginns","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00279398","article-title":"Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies","volume":"64","author":"Barneveld","year":"1983","journal-title":"Human Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0130","series-title":"Structural Analysis of the Human Glucocerebrosidase Genes DNA","first-page":"107","volume":"7","author":"Reiner","year":"1988"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM198703053161002","article-title":"A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease","volume":"316","author":"Tsuji","year":"1987","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0140","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.85.7.2349","article-title":"Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals","volume":"85","author":"Tsuji","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0150","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","article-title":"Identification of modifier genes in a mouse model of Gaucher disease","volume":"16","author":"Klein","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/367850","article-title":"Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease","volume":"72","author":"Tayebi","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0160","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM197411072911901","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease","volume":"291","author":"Brady","year":"1974","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0304-4165(81)90474-8","article-title":"Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation","volume":"673","author":"Furbish","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0022-3476(05)80444-5","article-title":"Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease","volume":"120","author":"Barton","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0185","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0190","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/archneur.1993.00540110088009","article-title":"The role of neurogenetics in Gaucher disease","volume":"50","author":"Brady","year":"1993","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0200","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1212\/WNL.43.10.1993","article-title":"Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease","volume":"43","author":"Patterson","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.1992.tb03618.x","article-title":"Gaucher patients with oculomotor abnormalities do not have a unique genotype","volume":"41","author":"Sidransky","year":"1992","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1203\/01.PDR.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0215","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(95)91688-1","article-title":"Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype","volume":"346","author":"Abrahamov","year":"1995","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0220","series-title":"Birth Defects Original Article Series","first-page":"109","article-title":"Renal transplantation in type II Gaucher disease","volume":"9","author":"Desnick","year":"1973"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0225","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410420412","article-title":"Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease","volume":"42","author":"Schiffmann","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0230","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mpd.2001.112171","article-title":"The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease","volume":"138","author":"Altarescu","year":"2001","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022410","article-title":"The saccadic and neurological deficits in type 3 Gaucher disease","volume":"6","author":"Benko","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1022578424693","article-title":"Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain","volume":"24","author":"Zirzow","year":"1999","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0245","first-page":"425","article-title":"Cerebrospinal-fluid infusion of alglucerase in the treatment of acuteneuronopathic Gauchers-disease","volume":"38","author":"Bembi B","year":"1995","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/01.wnl.0000247744.10990.e6","article-title":"Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease","volume":"68","author":"Lonser","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0255","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0260","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0265","doi-asserted-by":"crossref","first-page":"21200","DOI":"10.1073\/pnas.1119181109","article-title":"Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease","volume":"108","author":"Lu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10545-012-9515-9","article-title":"An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain","volume":"36","author":"Brady","year":"2013","journal-title":"J. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0275","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0285","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-12-802973-2.00009-4","article-title":"Epidemiology of alpha-synucleinopathies: from Parkinson disease to dementia with Lewy bodies","volume":"138","author":"Savica","year":"2016"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0290","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/WCO.0000000000000348","article-title":"The nonmotor features of Parkinson's disease: pathophysiology and management advances","volume":"29","author":"Reichmann","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0295","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0305","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","author":"Hernandez","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson's syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM: Mon. J. Assoc. Phys."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0315","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mgme.2001.3201","article-title":"Gaucher disease and parkinsonism: a phenotypic and genotypic characterization","volume":"73","author":"Tayebi N","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0320","first-page":"454","article-title":"Dementia with Lewy bodies and parkinsonism in a type 1 Gaucher disease patient","volume":"59","author":"Wong K","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0325","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with Parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to Parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0335","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0345","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz J","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0350","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0355","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pneurobio.2014.12.001","article-title":"Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle","volume":"125","author":"Sardi","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0360","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/acn3.185","article-title":"Variants associated with Gaucher disease in multiple system atrophy","volume":"2","author":"Mitsui","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0370","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1212\/WNL.0b013e31828f180e","article-title":"The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease","volume":"80","author":"Gan-Or Z","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0375","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000057","article-title":"Clinical course and prognosis in patients with Gaucher disease and parkinsonism","volume":"2","author":"Lopez","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0380","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archneur.65.10.1353","article-title":"The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations","volume":"65","author":"Goker-Alpan","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0385","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.24945","article-title":"Hyposmia and cognitive impairment in Gaucher disease patients and carriers","volume":"27","author":"McNeill","year":"2012","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0390","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0395","article-title":"Survival and dementia in GBa-associated Parkinson's disease: the mutation matters","author":"Cilia R","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0400","article-title":"Neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","author":"Liu G","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0405","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis MY","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000104","article-title":"GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis","volume":"2","author":"Mallett","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0415","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/brain\/aws174","article-title":"The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow","volume":"135","author":"Goker-Alpan","year":"2012","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0420","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/brain\/awu002","article-title":"Glucocerebrosidase is shaking up the synucleinopathies","volume":"137","author":"Siebert","year":"2014","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0425","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/07853890.2013.849003","article-title":"Glucocerebrosidase mutations and the pathogenesis of Parkinson disease","volume":"45","author":"Beavan","year":"2013","journal-title":"Ann. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0430","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0440","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0445","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0450","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","article-title":"Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention","volume":"82","author":"Mistry PK","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0455","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb NJ","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0460","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","article-title":"Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature","volume":"161","author":"Arends","year":"2013","journal-title":"Br. J Haematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0465","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc1411","article-title":"Biologically active shpingolipids in cancer pathogenesis and treatment","volume":"4","author":"Ogretmen B","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0470","first-page":"4560","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher","volume":"105","author":"Rosenbloom BE","year":"2005","journal-title":"Registry Blood"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0475","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in western Europe","volume":"36","author":"de Fost M","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0480","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei TH","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0485","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0490","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10","volume":"90","author":"Allen MJ","year":"1997","journal-title":"QJM: Mon. J. Assoc. Phys."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0495","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-007-0296-4","article-title":"Immune system irregularities in lysosomal storage disorders","volume":"115","author":"Castaneda JA","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0500","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker N","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0505","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0510","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0515","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair S","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0525","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1073\/pnas.82.19.6697","article-title":"Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins","volume":"82","author":"Ilyas AA","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CE.S93717","article-title":"Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy","volume":"11","author":"Serratrice C","year":"2016","journal-title":"Core Evid."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0535","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry PK","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0540","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1212\/01.wnl.0000314657.92762.0f","article-title":"Gaucher and Parkinson diseases: unexpectedly related","volume":"70","author":"Rogaeva","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0545","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bcmd.2014.05.007","article-title":"Outcome of early-treated type III Gaucher disease patients","volume":"53","author":"Lee NC","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0550","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ymgme.2016.02.008","article-title":"Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells","volume":"118","author":"Monestime","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0555","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0560","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk K","year":"2007","journal-title":"Molecular genetics and metabolism"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0565","first-page":"3","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","author":"Zimran A","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0570","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/gim.2013.154","article-title":"A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability","volume":"16","author":"Pastores GM","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0575","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores GM","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0580","doi-asserted-by":"crossref","first-page":"27108","DOI":"10.1016\/S0021-9258(18)47132-3","article-title":"N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing","volume":"269","author":"Platt","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0585","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj. J."},{"issue":"2008","key":"10.1016\/j.ymgme.2016.11.006_bb0590","first-page":"88","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"1992","journal-title":"Acta Paediatr. (Oslo, Norway)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0595","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0600","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2010","key":"10.1016\/j.ymgme.2016.11.006_bb0605","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox","year":"2000","journal-title":"Curr. Opin. Investig. Drugs (London, England)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0610","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0615","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0620","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0625","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0630","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ymgmr.2016.06.003","article-title":"Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry","volume":"8","author":"Ibrahim","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0635","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0640","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/ni.2143","article-title":"Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals","volume":"12","author":"Brennan","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0645","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.87.6.2334","article-title":"Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease","volume":"87","author":"Fink","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0650","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","article-title":"Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation","volume":"9","author":"Dunbar CE","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0655","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl M","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0660","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/cbic.200600217","article-title":"Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease","volume":"7","author":"Compain","year":"2006","journal-title":"Chembiochem: Eur. J. Chem. Biol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0665","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0670","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncb0805-766","article-title":"ERAD: the long road to destruction","volume":"7","author":"Meusser","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0675","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0680","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1039\/B915870G","article-title":"Glycosidase inhibition: assessing mimicry of the transition state","volume":"8","author":"Gloster","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0685","doi-asserted-by":"crossref","first-page":"43r","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0690","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna R","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0695","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0700","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0705","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1073\/pnas.1207889109","article-title":"Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease","volume":"109","author":"Panicker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0710","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0715","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0720","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0725","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant beta-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0730","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0735","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0740","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029861","article-title":"High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase","volume":"7","author":"Goldin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0750","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0755","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci: Off. J. Soc. Neurosci."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0760","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0765","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0770","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI117160","article-title":"Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease","volume":"93","author":"Holleran","year":"1994","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0775","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1203\/00006450-199601000-00020","article-title":"Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease","volume":"39","author":"Sidransky","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0780","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.95.5.2503","article-title":"Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0785","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0790","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0795","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0800","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1073\/pnas.1200941109","article-title":"Gaucher disease gene GBA functions in immune regulation","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0805","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0005-2760(81)90279-4","article-title":"Biliary excretion of glycolipid in induced or inherited glucosylceramide lipidosis","volume":"665","author":"Pentchev","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2016.11.006_bb0810","first-page":"627","article-title":"The Gaucher mouse","volume":"95","author":"Kanfer","year":"1982","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0815","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5966\/sctm.2014-0213","article-title":"Gaucher disease-induced pluripotent stem cells display decreased erythroid potential and aberrant myelopoiesis","volume":"4","author":"Sgambato JA","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0820","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2014.10.023","article-title":"iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease","volume":"9","author":"Woodard","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymgme.2016.11.006_bb0825","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:36:57Z","timestamp":1718890617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216303237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":165,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1096719216303237"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaucher disease: Progress and ongoing challenges","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}